Viracta Therapeutics, Inc.: Nasdaq/NYSE listing notice — Viracta receives Nasdaq notice for audit committee non-compliance; cure period through Dec 2025

Viracta Therapeutics, Inc.

Nasdaq notice dated Jan 13, 2025 for failing audit committee requirement under Rule 5605(c)(2).
Non-compliance triggered by resignation of board member Barry J. Simon, M.D. on Dec 18, 2024.
Cure period runs until the earlier of next annual meeting or Dec 18, 2025.
If annual meeting before June 16, 2025, compliance evidence due by June 16, 2025.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Viracta Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605(c)(2), 5605(c)(4)

Exact text from the filing

January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Viracta Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605(c)(2)

Exact text from the filing

January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the previously disclosed resignation of Barry J. Simon, M.D. from the Company’s board of directors (the “Board”) and audit committee on December 18, 2024, the Company was no longer in compliance with Nasdaq’s audit committee requirements under Nasdaq Listing Rule 5605(c)(2). In accordance with Nasdaq Listing Rule 5605(c)(4), the Company has been provided a cure period to regai

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-25-006711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.